<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076709</url>
  </required_header>
  <id_info>
    <org_study_id>P19.042</org_study_id>
    <nct_id>NCT04076709</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Muscle Relaxation During Laparoscopic Surgery</brief_title>
  <acronym>RELAX-LAP</acronym>
  <official_title>The Impact of Neuromuscular Relaxation and Nociception Guided Anaesthesia on Hemodynamic Variables During Lower Abdominal Laparoscopic Surgery: a Strategy Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many surgical procedures are performed using the laparoscopic approach. However, insufflation
      of the abdomen (pneumoperitoneum) has detrimental hemodynamic effects. The investigators
      intend to investigate the effect of deep neuromuscular block and nociception guided
      anaesthesia on hemodynamic variables during pneumoperitoneum for lower abdominal laparoscopic
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>30 minutes after installation of pneumoperitoneum</time_frame>
    <description>Mean arterial pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 minutes after installation of pneumoperitoneum</time_frame>
    <description>Mean arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>60 minutes after installation of pneumoperitoneum</time_frame>
    <description>Mean arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>5 minutes after installation of pneumoperitoneum</time_frame>
    <description>Cardiac output (l/min) as measured by non invasive arterial pulse contour anlysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>30 minutes after installation of pneumoperitoneum</time_frame>
    <description>Cardiac output (l/min) as measured by non invasive arterial pulse contour anlysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>60 minutes after installation of pneumoperitoneum</time_frame>
    <description>Cardiac output (l/min) as measured by non invasive arterial pulse contour anlysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>5 minutes after installation of pneumoperitoneum</time_frame>
    <description>Left ventricular ejection fraction measured by TEE</description>
  </other_outcome>
  <other_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>30 minutes after installation of pneumoperitoneum</time_frame>
    <description>Left ventricular ejection fraction measured by TEE</description>
  </other_outcome>
  <other_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>60 minutes after installation of pneumoperitoneum</time_frame>
    <description>Left ventricular ejection fraction measured by TEE</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Goal directed anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>goal directed anaesthesia</intervention_name>
    <description>Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25</description>
    <arm_group_label>Goal directed anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ASA 1-3;

          -  Scheduled for lower laparoscopic abdominal surgery;

          -  Ability to give oral and written consent;

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing neuromuscular function;

          -  Allergies to muscle relaxants, anesthetics or narcotics;

          -  A (family) history of malignant hyperthermia;

          -  Women who are or may be pregnant;

          -  Preexisting cardiac disease (any);

          -  Untreated or uncontrolled hypertension;

          -  COPD gold 3 or higher

          -  Preexistent esophageal pathology (stricture, tumor, diverticulum)

          -  Any increased risk factor for upper gastro intestinal tract bleed:

          -  History of GI surgery;

          -  History of GI bleed;

          -  Esophageal varices;

          -  Gastric or esophageal inflammation;

          -  Severe thrombocytopenia (less than 50k) or severely elevated INR (&gt;4).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martijn Boon, MD PhD</last_name>
    <phone>+31 71-5262301</phone>
    <email>m.boon@lumc.nl</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Martijn Boon</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

